Silexion Therapeutics (SLXN) Shares Fall on Announced 1-for-10 Reverse Split

Silexion Therapeutics (SLXN) shares declined on May 26, 2026, after the biotech company announced a 1-for-10 reverse stock split aimed at regaining compliance with Nasdaq’s minimum $1 bid price rule. The reverse split takes effect at the market open on May 27, 2026, consolidating every ten outstanding shares into one. SLXN had traded below the threshold for an extended period, prompting a delisting notice from the exchange. The move is the latest attempt by the struggling biotech to preserve its listing status. Shareholders approved the reverse split proposal earlier this month, giving the board discretion to set the ratio and timing. The action mechanically elevates the nominal share price but does not change the company’s underlying fundamentals. SLXN shares fell in extended trading following the announcement.